RetinalGenix Technologies

RTGN

Medical - Devices · Healthcare

Price

$4.00

+0.00 (+0.00%)

Market Cap

$75.4M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+30.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 14.3M (2021) → 18.6M (2025)

RetinalGenix Technologies is a small healthcare company focused on building devices that scan and analyze the human eye. Its core product is an AI-assisted retinal imaging system designed to help doctors detect diseases like diabetic retinopathy and other conditions that can cause blindness. The main customers are eye care clinics, hospitals, and healthcare providers looking for faster, more affordable screening tools.

The company makes money by selling its imaging hardware and related software to medical facilities, though it is still in early stages and currently generates little to no revenue. It operates primarily in the United States and has a very small market presence with a market cap of around $100 million. The key risk here is significant — the company is burning cash, has negative returns on invested capital, and must still prove its technology can win regulatory approvals, secure paying customers, and scale before it runs out of funding.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+31.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$83,040/ year

↓ Declining (-78% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

66.8%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$14,774 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

RetinalGenix Technologies has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial